Sugi Predict

Sugi Predict / Compounds / SCHEMBL4806049

SCHEMBL4806049

SCHEMBL4806049

C#CC(=O)c1ccccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.60
▸ CES1 P23141 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.58
▸ POLB P06746 2/20 0.54
▸ CYP1A2 P05177 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ ERCC5 P28715 1/20 0.46
▸ FEN1 P39748 1/20 0.46
▸ KMT2A Q03164 3/20 0.44
▸ TSHR P16473 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ SMO Q99835 1/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30725459 1.00 CES2 (0.60) CES2CES1ALDH1A1POLBCYP1A2
SCHEMBL4000363 0.80 CES2 (0.58) CES2CES1ALDH1A1POLBCYP1A2
SCHEMBL28677921 0.77 KDM4E (0.54) ALDH1A1HPGDCYP2C19KMT2ATSHR
SCHEMBL4707495 0.77 CES2 (0.54) CES2CES1ALDH1A1POLBCYP1A2
Methyl Alcohol SCHEMBL28939417 0.77 CES2 (0.54) CES2CES1ALDH1A1POLBCYP1A2
SCHEMBL19332963 0.76 CES2 (0.58) CES2CES1ALDH1A1HPGDERCC5
SCHEMBL18104841 0.76 NPC1 (0.43) ALDH1A1POLBHPGDKMT2AMEN1
SCHEMBL11643111 0.76 HPGD (0.46) ALDH1A1POLBHPGDERCC5FEN1
SCHEMBL12204783 0.76 ALDH1A1 (0.39) CES2CES1ALDH1A1POLBKMT2A
SCHEMBL17244263 0.76 MAPT (0.50) ALDH1A1POLBHPGDKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12329755-B2 Bromodomain inhibitors to target therapy-resistant cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-17 — — US disclosed
CN-119213094-A Medical silicone pressure sensitive adhesive composition 埃肯有机硅法国简易股份公司 2024-12-27 — — CN disclosed
US-20240009343-A1 MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION ELKEM SILICONES FRANCE SAS (FR) 2024-01-11 — — US disclosed
CN-117157112-A Medical silicone pressure sensitive adhesive composition 埃肯有机硅（上海）有限公司 2023-12-01 — — CN disclosed
WO-2023213430-A1 MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION ELKEM SILICONES FRANCE SAS (FR) 2023-11-09 — — WO disclosed
EP-4273204-A1 MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION ELKEM SILICONES France SAS (FR) 2023-11-08 — — EP disclosed
CN-116782890-A Patch coated with capsaicin-containing silicone gel 埃肯有机硅（上海）有限公司 2023-09-19 — — CN disclosed
EP-4240433-A1 MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION Elkem Silicones Shanghai Co., Ltd. (CN) 2023-09-13 — — EP disclosed
US-20220296592-A1 BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2022-09-22 — — US disclosed
US-20220296592-A1 BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2022-09-22 — — US disclosed
WO-2017158249-A1 SKIN-ADHESIVE SILICONE GEL BLUESTAR SILICONES FRANCE SAS (FR) 2017-09-21 — — WO disclosed
WO-2017051083-A1 ITEM THAT ADHERES TO THE SKIN BLUESTAR SILICONES FRANCE SAS (FR) 2017-03-30 — — WO disclosed
WO-2017051085-A1 SILICONE COMPOSITION AND PROCESS USEFUL FOR IMPROVING THE CREASE RESISTANCE AND ABRASION RESISTANCE OF AIRBAGS, INTENDED FOR PROTECTING A VEHICLE OCCUPANT BLUESTAR SILICONES FRANCE SAS (FR) 2017-03-30 — — WO disclosed
WO-2016207498-A1 SKIN-ADHESIVE ITEM BLUESTAR SILICONES FRANCE SAS (FR) 2016-12-29 — — WO disclosed
US-20160319086-A1 NOVEL PHOTOACTIVATABLE SYSTEM FOR INHIBITING HYDROSILYLATION BLUESTAR SILICONES FRANCE SAS (FR) 2016-11-03 — — US disclosed
CN-101460569-A Adhesion promoting additive AVERY DENNISON CORP (US) 2009-06-17 — — CN disclosed
US-7320994-B2 Triazole derivatives as tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2008-01-22 — — US disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 — — US disclosed
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists ELI LILLY COMPANY (US) 2005-10-27 — — US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists TACR1, TACR2, BDKRB1 CES2 2856/4885CES1 949/4885ALDH1A1 1408/4885
US-20220296592-A1 BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER BRD1, SMARCE1, SMARCA1 CES2 2019/4885CES1 2452/4885ALDH1A1 2472/4885
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 CES2 3878/4885CES1 2197/4885ALDH1A1 1988/4885
US-12329755-B2 Bromodomain inhibitors to target therapy-resistant cancer BRD1, SMARCE1, SMARCA1 CES2 2019/4885CES1 2452/4885ALDH1A1 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.